Welcome to CDC stacks |
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Cost-Effectiveness of Aspirin Use Among Persons With Newly Diagnosed Type 2 Diabetes
  • Published Date:
    Mar 23 2010
  • Source:
    Diabetes Care. 33(6):1193-1199.
Filetype[PDF-159.21 KB]


Details:
  • Alternative Title:
    Diabetes Care
  • Description:
    OBJECTIVE

    To assess the long-term cost-effectiveness of aspirin use among adults aged ≥40 years with newly diagnosed type 2 diabetes.

    RESEARCH DESIGN AND METHODS

    We used a validated cost-effectiveness model of type 2 diabetes to assess the lifetime health and cost consequences of use or nonuse of aspirin. The model simulates the progression of diabetes and accompanying complications for a cohort of subjects with type 2 diabetes. The model predicts the outcomes of type 2 diabetes along five disease paths (nephropathy, neuropathy, retinopathy, coronary heart disease, and stroke) from the time of diagnosis until age 94 years or until death.

    RESULTS

    Over a lifetime, aspirin users gained 0.31 life-years (LY) or 0.19 quality-adjusted LYs (QALYs) over nonaspirin users, at an incremental cost of $1,700; the incremental cost-effectiveness ratio (ICER) of aspirin use was $5,428 per LY gained or $8,801 per QALY gained. In probabilistic sensitivity analyses, the ICER was <$30,000 per QALY in all of 2,000 realizations in two scenarios.

    CONCLUSIONS

    Regular use of aspirin among people with newly diagnosed diabetes is cost-effective.

  • Document Type:
  • Collection(s):
  • Main Document Checksum:
No Related Documents.
You May Also Like: